These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29764158)

  • 21. Immunotherapy in Breast Cancer- Paving New Roads?
    Truica CI; Cleary AS
    Curr Mol Pharmacol; 2016; 9(3):208-216. PubMed ID: 26177646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy opportunities in breast cancer].
    Pusztai L; Ladányi A; Székely B; Dank M
    Magy Onkol; 2016 Mar; 60(1):34-40. PubMed ID: 26934349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for breast cancer: past, present, and future.
    Spellman A; Tang SC
    Cancer Metastasis Rev; 2016 Dec; 35(4):525-546. PubMed ID: 27913998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging immunotherapeutic strategies for the treatment of breast cancer.
    Huppert LA; Mariotti V; Chien AJ; Soliman HH
    Breast Cancer Res Treat; 2022 Jan; 191(2):243-255. PubMed ID: 34716870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives.
    de la Cruz-Merino L; Chiesa M; Caballero R; Rojo F; Palazón N; Carrasco FH; Sánchez-Margalet V
    Int Rev Cell Mol Biol; 2017; 331():1-53. PubMed ID: 28325210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.
    Ravelli A; Reuben JM; Lanza F; Anfossi S; Cappelletti MR; Zanotti L; Gobbi A; Milani M; Spada D; Pedrazzoli P; Martino M; Bottini A; Generali D;
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):689-702. PubMed ID: 25927868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapy for the Prevention and Treatment of Breast Cancer].
    Svoboda M; Navrátil J; Slabý O
    Klin Onkol; 2015; 28(6):416-25. PubMed ID: 26673991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of immune evasion in breast cancer.
    Bates JP; Derakhshandeh R; Jones L; Webb TJ
    BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Immunotherapy Strategies in Breast Cancer.
    Yu LY; Tang J; Zhang CM; Zeng WJ; Yan H; Li MP; Chen XP
    Int J Environ Res Public Health; 2017 Jan; 14(1):. PubMed ID: 28085094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The emerging world of breast cancer immunotherapy.
    Nathan MR; Schmid P
    Breast; 2018 Feb; 37():200-206. PubMed ID: 28583398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging immunotherapy strategies in breast cancer.
    Page DB; Naidoo J; McArthur HL
    Immunotherapy; 2014; 6(2):195-209. PubMed ID: 24491092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Blockade Inhibition in Breast Cancer.
    Voutsadakis IA
    Anticancer Res; 2016 Nov; 36(11):5607-5622. PubMed ID: 27793883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines.
    Hashemzadeh N; Dolatkhah M; Adibkia K; Aghanejad A; Barzegar-Jalali M; Omidi Y; Barar J
    Life Sci; 2021 Apr; 271():119110. PubMed ID: 33513401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in Combining Radiation and Immunotherapy in Breast Cancer.
    Nguyen AT; Shiao SL; McArthur HL
    Clin Breast Cancer; 2021 Apr; 21(2):143-152. PubMed ID: 33810972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.
    Jalalvand M; Darbeheshti F; Rezaei N
    Immunotherapy; 2021 May; 13(7):587-603. PubMed ID: 33775102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell-based breast cancer immunotherapy.
    Pilipow K; Darwich A; Losurdo A
    Semin Cancer Biol; 2021 Jul; 72():90-101. PubMed ID: 32492452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapeutics for breast cancer.
    Criscitiello C; Curigliano G
    Curr Opin Oncol; 2013 Nov; 25(6):602-8. PubMed ID: 24076578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer vaccines: Heeding the lessons of the past to guide a path forward.
    Solinas C; Aiello M; Migliori E; Willard-Gallo K; Emens LA
    Cancer Treat Rev; 2020 Mar; 84():101947. PubMed ID: 31926403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.